Search BioPortfolio:
BioPortfolio
Web
Home
Marketing Services
News
Reports
Company Profiles
InDepth
Drug Discovery
Careers
Conferences
Videos
Search
Contact
Items Ordered:
Cart Value:
New Products:
1.
The Indian Pharmaceutical Market Analysis and Forecasts 2008-2023
2.
The Convergence of Biomarkers and Diagnostics: Therapy area analyses, key products and future trends
3.
Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard
4.
Commercial Insight: CNS Market Overview - Commercial dynamics and outlook of the neurology, pain and psychiatry market sectors
5.
Commercial and Pipeline Insight: HRT for Menopausal Symptoms A new class restores an old market
6.
Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
7.
Pipeline Insight: Non-Small Cell Lung Cancer - Pipeline set to offer only modest improvements
8.
Stakeholder Opinions: Heart Failure - When drugs do not work
9.
Pipeline Insight: Breast Cancer - Recent approvals increase pressure on pipeline candidates
10.
Commercial and Pipeline Insight: ADHD - Immature adult market continues to offer greatest commercial potential
Best Sellers:
1.
Primary Brain Cancer
2.
Drug Delivery Global Industry Guide
3.
The Convergence of Biomarkers and Diagnostics: Therapy area analyses, key products and future trends
4.
The Fastest Growing Biotechnology Companies: Growth strategies, comparative analyses and company profiles
5.
BioNewsCast Press Release Distribution Service
6.
Pharmaceutical Growth Opportunities in Brazil, Russia, India and China - Healthcare reform, market dynamics and key players
7.
Cell Therapy - Technologies, Markets and Companies
8.
Cytogenetics - technologies, markets and companies
9.
Molecular Diagnostics Markets
10.
The Future of Targeted Therapeutics Key technologies, new therapy area applications and leading players
The Deployment of Antibody Technologies for the Advancement of Cancer Therapeutics
The discovery of new cancer therapeutics has seen a significant shift towards biologicals as an alternative to small molecule drugs. Targeted biologics utilizing monoclonal antibody (mAb)-based technologies have rapidly developed into one of the major market segments of the pharmaceutical industry. By analyzing R&D pipelines and the platform technologies in use today, it is possible to better predict where the market will be in the next decade and to envisage which new innovative therapies will become market successes.
Research highlights
The second wave of therapeutic antibody technologies, encompassing optimized full size, fully human antibodies as well as the bits and pieces of individual antibody fragments and alternative binding domains/scaffolds is driving the formation of innovative technology platforms. While biotechs have led the race towards the discovery of novel technologies, big pharma has taken over the reigns for the development of many of these future therapeutic drugs.
In this report, BioSeeker Group has surveyed and categorized the technology platform status of over 100 companies and identified over 150 unique platforms that are shaping the current and future pipeline of monoclonal antibody therapeutics.
Scope of this report:
* A single source for market wide competing monoclonal antibody technologies in oncology
* Thorough examination of the leading cancer therapeutic antibody technologies
* The race towards the next generation of therapeutic antibodies
* Competing platforms for expression, delivery, and modification of antibodies
This report will:
* improve your competitor analysis
* allow you to assess the strengths/weaknesses of competing technologies
* outline R&D alignments
* allow you to assess the direction of future technologies
Pages: 163 April 2008
Table of Contents
Price: $3,595.00 / GBP1,797.50
Buy Biotechnology Management Reports online with BioPortfolio's secure E-Commerce portal.